Mar 22, 2021 | News, Promotions
ExonanoRNA LLC., based in Columbus, Ohio, and MDimune Inc., headquartered in Seoul, South Korea, have entered into a service agreement to develop targeted siRNA therapy in oncology application on October 8th, 2021. By combining ExonanoRNA’s RNA NanoParticle Displaying... Mar 17, 2020 | Uncategorized
Columbus, Ohio – A new breakthrough study was published in Nature Communications recently. This study was led by our president, Dr. Peixuan Guo, in addition to our VP, Mario Vieweger, as a co-author. Paclitaxel is a very common chemotherapeutic drug, but due to its... Feb 14, 2020 | Uncategorized
ExonanoRNA is donating research reagents to qualified individuals or organizations developing new medical treatments for the novel coronavirus. This new coronavirus is a member of a family of RNA viruses, and the typical genome for a generic coronavirus is a single... Jan 6, 2020 | Uncategorized
ExonanoRNA is pleased to announce that it has been named one of the “10 Most Innovative Healthcare Nanotech Companies to Watch” by Insights Care Magazine. This article outlines our company’s mission and history, as well as our goals for the future. You can read the... Dec 19, 2019 | Promotions
We want to wish you a merry Christmas this year by providing a special 15% discount code, Merry2019, for our products and services until December 31, 2019. Among our featured products are: 1. Custom Oligo synthesis (RNA, 2’F-RNA, 2’-OMethyl RNA, LNA and others, 0.2-60...
